LIAN - French biotech Nanobiotix rebounds to post best ever 47% intraday gain

• ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. ( NASDAQ: NBTX ) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes.
• Nanobiotix ( NBTX ) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K.
• This quarter, Nanobiotix ( NBTX ) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma.
• Its partner for the program, LianBio ( LIAN ) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

For further details see: